Results 191 to 200 of about 429,003 (305)

Reduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Reduced‐port laparoscopic colectomy (RPLC) for colorectal cancer offers modest intraoperative benefits, including shorter operative time and lower blood loss, while maintaining comparable postoperative recovery, lymph node yield, and complication rates to multi‐port laparoscopic colectomy (MPLC).
Ayesha Shaukat   +9 more
wiley   +1 more source

One‐Year Changes in Frailty Components After Curative Minimally Invasive Surgery for Colorectal Cancer in Older Patients

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Frailty predicts outcomes after colorectal cancer surgery, but postoperative changes remain unclear. We previously reported improvement in FRAIL Scale‐based frail/pre‐frail status 1 year after curative minimally invasive surgery (MIS).
Hajime Ushigome   +9 more
wiley   +1 more source

Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance

open access: yes
openLa disbiosi è una condizione di mancato equilibrio della flora microbica che contribuisce all’insorgenza di stati infiammatori, cancro al colon-retto (CRC), e può anche interferire con la risposta alle terapie. Se la correlazione tra insorgenza del
ISMA, GIOIA
core  

Biological Resectability in Colorectal Liver Metastases: A Nomogram‐Based Continuous Risk Model to Define Borderline Disease

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
KRAS mutation demonstrated a prognostic impact according to primary tumor sidedness, independent of tumor morphology, in patients undergoing hepatectomy for colorectal liver metastases. A nomogram integrating biological and clinicopathological factors was developed to provide continuous biological risk assessment.
Yuzo Umeda   +9 more
wiley   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy